Merck announcd today that it consummated a second deal with Ablynx that could earn the latter up to 1.7 B euros after milestones and commercialization. The deal calls for Merck to pay 20 M euros upfront and provide up to 10.7 M euros in R&D funding over the next year to Ablynx in exchange for access to their nanobodies technology. The research will be directed to predetermined targets that control immunomodulating functions as potential cancer therapies - an area of Merck focus and strength.
Ablynx is responsible for helping with discovery and Merck will be responsible for development, manufacturing and commercialization. This second deal comes n the heels of a 2012 pact between the two aimed at ion channel elements important to neurological diseases, and others like hypertension, diabetes and cancers. The current deal will allow Merck to build on its early clinical success with MK-3475 a seemingly potent cancer immunomodulator. See Fierce Biotech and FirstWordPharma.
Posted by Bruce Lehe Feb 3rd 2014.